CEL-SCI Corporation has announced a strategic partnership with a leading Saudi Arabian pharmaceutical company to advance the regulatory and commercial activities for its cancer drug, Multikine, in Saudi Arabia. The partnership will involve filing for Breakthrough Medicine Designation with the Saudi Food and Drug Authority (SFDA), with a response expected within approximately 60 days. Upon approval, Multikine will be available for patient access and reimbursement in the Kingdom. The collaboration leverages the expertise of CEL-SCI's local partner to expedite Multikine's entry into the market. Additionally, several prominent Saudi investment funds have shown interest in investing in CEL-SCI and its initiatives, highlighting the potential for a broader joint venture to address the Middle East and North Africa market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.